Improved Periorbital Satisfaction After Combined Mid and Upper Facial Treatment With Hyaluronic Acid Fillers and OnabotulinumtoxinA: Effectiveness and Safety Results From a Post-Marketing Study.

[BACKGROUND] The periorbital region is among the first areas noticed in an individual, playing a crucial role in facial attractiveness and emotional expression.

[AIMS] Open-label study to evaluate the impact of mid and upper facial treatment with hyaluronic acid (HA) fillers and onabotulinumtoxinA (onabotA) on periorbital satisfaction and appearance.

[PATIENTS/METHODS] Eligible participants received ≥ 2 HA fillers (VYC-15L, VYC-17.5L, VYC-20L) in the mid and upper face on Day 1, and VYC-15L in the infraorbital hollow (IOH) on Day 30 if needed. Optional touch ups followed after 14 days. OnabotA was administered to glabellar lines (GL) and/or lateral canthal lines (LCL) on Day 60. The primary endpoint was the change from baseline in FACE-Q Satisfaction with Eyes to Day 90. Additional effectiveness assessments and safety were monitored throughout.

[RESULTS] Enrolled participants were 86.3% White and 13.7% Asian. FACE-Q Rasch-transformed scores increased from baseline to Day 90 by 55.5 points (p < 0.0001). Investigator-assessed infraorbital appearance improved in 69.4% of participants at Day 30 (p = 0.063 vs. baseline) and in 100% at Day 90. Periorbital appearance improved in 91.7% (investigator) and 95.8% (participant) of participants at Day 30, reaching 100% for both at Day 90 (nominal p < 0.0001 vs. baseline). IOH severity gradually decreased, with 59.8% of participants showing minimal or no severity at Day 90 versus 0% at baseline, and infraorbital volume increased. No unexpected safety signals were observed.

[CONCLUSIONS] Combination of HA fillers and onabotA treatments improved eye satisfaction, periorbital and infraorbital appearance, IOH severity, and infraorbital volume, demonstrating direct and indirect treatment effects.